Core Insights - HaiXi Pharmaceutical (02637.HK) was listed on the Hong Kong stock market on October 20, with a market capitalization of approximately HKD 8 billion [1] - The company is in the commercialization stage, with 15 generic drugs approved by the National Medical Products Administration and 4 innovative drugs in the research pipeline targeting oncology, ophthalmology, and respiratory diseases [1] - The revenue projections for HaiXi Pharmaceutical from 2022 to 2024 are HKD 213 million, HKD 317 million, and HKD 467 million, respectively, with net profits of HKD 69 million, HKD 118 million, and HKD 136 million [1] Company Overview - HaiXi Pharmaceutical has 15 commercialized generic drugs primarily used for treating digestive, cardiovascular, endocrine, neurological, and inflammatory diseases [1] - Among the 15 generic drugs, 4 are included in the national centralized procurement program [1] - The company has a research team of 112 personnel and a sales team of only 36 employees [1] Business Strategy - The company plans to continue supporting the development of innovative drugs through the sales of generic drugs [2] - Key operational strategies include increasing R&D investment, enhancing commercialization capabilities, improving R&D capacity, conducting GMP compliance checks, and focusing on talent recruitment and retention [2]

Group 1 - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has had his detention lifted, allowing him to resume his duties, which enhances investor confidence in the company's future development [1] - FTSE Russell announced the inclusion of BeiGene and WuXi AppTec in the FTSE China A50 Index, reflecting the increasing importance of A-share companies in the global capital market and foreign investment interest in China's innovative drug sector [2] - Otsuka Pharmaceutical's application for the targeted drug, Belimumab injection, for IgA nephropathy has been accepted, potentially filling a market gap in a field with limited treatment options and providing a new growth point for the company [3] Group 2 - Ruizhi Pharmaceutical announced a partnership to establish a fund focused on investing in innovative drugs and medical devices, which will enhance the company's resource reserves and align with current industry trends [4] - Menova's subsidiary has received approval for Mosapride Citrate Tablets in China, which is expected to generate new revenue growth for the company and strengthen its position in the pharmaceutical industry [5]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的枸橼酸莫沙必利片《药品注册证书》，现 将相关情况公告如下： 证券代码：603538 证券简称：美诺华 公告编号：2025-097 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于全资子公司获得枸橼酸莫沙必利片 药品注册证书的公告 药品适应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎） 引起的消化道症状，包括烧心、嗳气、恶心、呕吐、早饱、上腹胀、上腹痛等。 国产药品注册的申请并获得受理。截至本公告日，公司已投入研发费用为人民币 由于医药产品的行业特点，该药品未来销售情况可能受到政策变化、市场需 求、同类型药品市场竞争等多种不确定因素影响，具有较大不确定性，敬请广大 投资者注意投资风险。 特此公告。 一、药品相关信息 宁波美诺华药业股份有限公司 本品符合药品注册的有关要求 ...

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company in expanding its product portfolio [2] - Mosapride Citrate is expected to enhance the company's competitive position in the pharmaceutical market [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Core Viewpoint - Meinuohua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product [1] Group 1 - The drug is indicated for improving gastrointestinal symptoms caused by decreased gastrointestinal motility, such as functional dyspepsia and chronic gastritis [1] - Symptoms addressed by the drug include heartburn, belching, nausea, vomiting, early satiety, upper abdominal bloating, and upper abdominal pain [1]

Core Viewpoint - Meihua's subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Mosapride Citrate Tablets, which are indicated for improving gastrointestinal symptoms caused by reduced gastrointestinal motility [1] Group 1 - The approved drug is intended for symptoms such as heartburn, belching, nausea, vomiting, early satiety, upper abdominal distension, and upper abdominal pain [1]